IL17A and Miyoshi myopathy: There have been basic studies on IL-17A promoting the occurrence of MM bone disease, promoting the proliferation of MM cells, increasing the viability of MM cells, and inhibiting immune function, although the mechanism of further action is still unclear (20–22).